BioSenic secures key funding as it pushes for phase 3 trial
Biosenic, a company specializing in serious autoimmune and inflammatory diseases and cell therapy, has secured funding from Singapore-based TrialCap, in a bid to accelerate its phase 3 clinical development.
Graft Versus Host Disease Trial Cap Global Tech Opportunities Bio Developments Markets Amp Regulations Cell Amp Gene Therapies
Source: biopharma-reporter.com